At CPHI Frankfurt 2025, SGD Pharma highlighted key developments in pharmaceutical glass packaging, from advanced vial technologies to expanded manufacturing capabilities.

For SGD Pharma, it was an opportunity to present innovations designed to support drug protection, manufacturing efficiency and supply chain reliability.

The highlights included the integration of Alphial, new molded and tubular glass solutions, and the development of specialized laboratory services.

Strengthening Tubular Glass Expertise with Alphial

One of the key developments highlighted at CPHI Frankfurt 2025 was SGD Pharma's acquisition of Alphial, an Italian manufacturer specializing in tubular glass packaging.

The acquisition expanded SGD Pharma's European industrial footprint and strengthened its expertise in pharmaceutical ampoules, vials and Ready-to-Use (RTU) solutions.

It also complemented the Group's established molded glass manufacturing capabilities.

By bringing together molded and tubular glass expertise, SGD Pharma broadened its portfolio and strengthened its ability to support different pharmaceutical packaging requirements.

Pharmaceutical Glass Packaging Innovations at CPHI 2025

SGD Pharma presented several solutions designed to address specific pharmaceutical manufacturing challenges.

These innovations focused on glass performance, filling efficiency, drug protection and packaging flexibility.

SEALIAN: Advanced Glass Surface Technology

SEALIAN is an internal hydrophobic surface treatment developed for pharmaceutical glass vials.

The technology helps improve product recovery and supports the appearance of lyophilized formulations.

It also addresses specific challenges related to interactions between pharmaceutical products and glass surfaces.

SEALIAN illustrates how specialized glass treatments can help pharmaceutical manufacturers meet demanding formulation requirements.

IDENCY: Combining Glass Performance and Filling Compatibility

The IDENCY range combines the mechanical advantages of molded glass with external dimensions comparable to standard tubular vials.

At CPHI Frankfurt 2025, SGD Pharma highlighted the expansion of this range to include 6 mL, 10 mL and 20 mL formats.

These solutions provide pharmaceutical manufacturers with additional options when selecting glass packaging for their filling operations.

Sterinity EZ-fill®: Ready-to-Use Glass Packaging

SGD Pharma also highlighted Sterinity EZ-fill®, a ready-to-use molded glass vial solution.

Ready-to-use packaging can help pharmaceutical manufacturers simplify certain preparation steps before filling.

This approach supports the industry's growing interest in flexible manufacturing processes and efficient pharmaceutical operations.

Velocity® Vials: Supporting Fill-and-Finish Performance

Velocity® Vials combine Type I tubular glass with Corning's external low-friction coating technology.

The solution is designed to improve vial handling during pharmaceutical fill-and-finish operations.

Its reported performance benefits include:

  • 20–50% improvement in fill-and-finish efficiency.
  • Up to 96% fewer particulates.
  • Reduced friction during vial handling.

These features demonstrate how glass surface technologies can contribute to manufacturing efficiency.

Proseal+: Advanced Glass Packaging Technology

Proseal+ was another innovation highlighted at CPHI Frankfurt 2025.

The solution reflects SGD Pharma's continued development of specialized glass packaging technologies for pharmaceutical applications.

Together with the other innovations presented, it demonstrates the importance of adapting glass packaging to specific product and manufacturing requirements.

Expanding SGD Pharma Lab Services

Alongside its packaging portfolio, SGD Pharma presented the development of its Lab Services.

These specialized analytical capabilities support pharmaceutical and biopharmaceutical companies, as well as CMOs, CDMOs and glass packaging manufacturers.

The services complement SGD Pharma's industrial expertise by providing technical support for glass packaging applications.

This development reflects the Group's ambition to support customers beyond glass container manufacturing.

Sustainability and Industrial Transformation

Sustainability was another important theme at CPHI Frankfurt 2025.

SGD Pharma highlighted its environmental commitments and investments in more efficient glass manufacturing.

The Group's climate targets include:

  • A 42% reduction in Scope 1 and 2 emissions by 2030, compared with 2022.
  • A 25% reduction in Scope 3 emissions by 2030, compared with 2022.

These targets form part of SGD Pharma's decarbonization strategy.

The company also highlighted its EcoVadis Platinum recognition, reflecting its progress in environmental, social and governance performance.

Together, these initiatives demonstrate how SGD Pharma combines industrial development with environmental responsibility.

Building on the Innovations Presented at CPHI Frankfurt 2025

CPHI Frankfurt 2025 marked an important moment in SGD Pharma's development.

The innovations presented reflected several strategic priorities: expanding manufacturing capabilities, improving pharmaceutical glass performance and strengthening technical expertise.

From the integration of Alphial to advanced vial technologies and laboratory services, these developments highlighted the breadth of SGD Pharma's offering.

Today, they remain relevant to pharmaceutical manufacturers seeking reliable packaging solutions and technical support.

Discover SGD Pharma's pharmaceutical glass packaging solutions and contact our experts to discuss your specific requirements.